Preventive Effect of Lactoferrin Intake on Anemia in Female Long Distance Runners

Koikawa, Natsue; Nagaoka, Isao; Yamaguchi, Masahiro; Hamano, Hirokazu; Yamauchi, Koji; Sawaki, Keisuke

doi:10.1271/bbb.70383

Cited by 24 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Another study conducted by Natsue Koikawa et al amongst Japanese runners, comparing efficacy of lactoferrin and OFS reported a decrease in ferritin stores in both the arms after 8 weeks of therapy. 22 Since there is an inversely proportionally relationship between serum iron concentration (SIC) and TIBC/UIBC hence only a marginal fall was noted amongst these parameters in the OFS arm of our study. 23 In Group II and Group III of our study a significant rise in transferrin saturation (p<0.05) with an increase in SIC was noted.…”

Section: Resultsmentioning

confidence: 67%

A Comparative Study to Evaluate the Efficacy of Oral Lactoferrin Fortified Bovine Colostrum with Oral Iron in the Treatment of Iron Deficiency Anemia

Ramakrishnan¹,

Sivaraman²,

Dutta³

et al. 2018

IJMEDPH

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 67%

A Comparative Study to Evaluate the Efficacy of Oral Lactoferrin Fortified Bovine Colostrum with Oral Iron in the Treatment of Iron Deficiency Anemia

Ramakrishnan¹,

Sivaraman²,

Dutta³

et al. 2018

IJMEDPH

View full text Add to dashboard Cite

“…It was reported that, when infants were fed an LF-added powdered infant formula, the hematocrit value was higher compared with that in the group fed the conventional powdered infant formula [15]. Increases in the mean corpuscular volume (MCV) and hemoglobin (MCH) after LF ingestion compared with those before ingestion were observed in female marathon runners [16]. These findings show that LF increases red blood cell-related indices.…”

Section: Resultsmentioning

confidence: 99%

Radioprotection of mice by lactoferrin against irradiation with sublethal X-rays

Nishimura¹,

Homma-Takeda²,

Kim

et al. 2014

Journal of Radiation Research

View full text Add to dashboard Cite

The influence of a host defense protein, lactoferrin (LF), contained in exocrine secretions such as milk, on radiation disorder was investigated. A total of 25 C3H/He mice in each of two groups were maintained with 0.1% LF-added and LF-free diets, respectively, for one month. The mice were then treated with single whole-body X-ray irradiation at a sublethal dose (6.8 Gy), and the survival rate after irradiation was investigated. The survival rate at 30 d after irradiation was relatively higher in the LF group than in the control group (LF-free), (85 and 62%, respectively). The body weight 15 d after X-ray irradiation was also significantly greater in the LF group than in the control group. The hemoglobin level and hematocrit value were higher in the LF group at 5 d before X-ray irradiation. Another 52 mice underwent whole-body X-ray irradiation at the sublethal dose (6.8 Gy), and then LF was intraperitoneally injected once at 4 mg/animal to half of them. The survival rate in LF-treated mice 30 d after irradiation was 92%, significantly higher than in mice treated with saline (50%) (P = 0.0012). In addition, LF showed hydroxyl radical scavenger activity in vitro. These findings suggest that LF may inhibit radiation damage.

show abstract

“…The Panel notes the low dose. One RCT with 16 healthy female long distance runners studied the effect of 1.8 g lactoferrin plus 6 mg iron per day given over 4 weeks on iron haemostasis, red blood cell parameters and blood lactate concentration after intensive exercise, but did not include safety relevant endpoints (Koikawa et al, 2008). The authors did not report on the occurrence of adverse effects.…”

Section: Studies In Adultsmentioning

confidence: 99%

Scientific Opinion on bovine lactoferrin

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to carry out the additional assessment of "lactoferrin" as a food ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and objections of a scientific nature raised by Member States. Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for a variety of foods. For infants with an age of 0 -6 months, the applicant has estimated an intake of approximately 200 mg per kg bodyweight and 1.2 g bLF per day at the proposed use level. For adults, the mean and 95 th percentile daily intakes were calculated to be about 1.4 g and 3.4 g for an adult person. The toxicological information provided by the applicant included information from an in vitro genotoxicity study, a single dose study, a four week and a thirteen week oral repeated dose study in rats. The Panel notes that the estimated intake of "lactoferrin" for infants up to the age of one year of approximately 210 mg/kg bw per day would be around ten times lower than the highest dose (2,000 mg/kg bw per day) tested in the subchronic thirteen week rat study, which did not show adverse effects related to bLF. For adults above 19 years of age the proposed intake is approximately 100 times lower. This level of anticipated intake is considered a high intake scenario as opposed to a worst-case situation. The data provided suggest the absence of adverse effects of lactoferrin at the proposed levels of consumption. The Panel concludes that the novel food ingredient bLF is safe under the proposed uses and use levels. © European Food Safety Authority, 2012 KEY WORDSBovine lactoferrin, novel food, ingredient Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF in isolated and purified form. bLF is an iron-binding glycoprotein of approximately 77 kDa and consists of a single polypeptide chain of about 700 amino acids. The sequence homology between human and bLF is about 70 %. The tertiary structure of this glycoprotein has two ironbinding sites, giving it the capability to bind two Fe 3+ ions per molecule of protein. Batch testing confirmed that the product complies with the given specifications. bLF from skimmed milk is concentrated via ion exchange and is subsequently subjected to filtration steps. Ultimately the bLF is dried by means of spray drying. The applicant provided sufficient information regarding the specification, manufacture, composition and stability of bLF.The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for foods such as nonalcoholic beverages, cakes and pastries, products derived from cheese, milk-based products, cold snacks...

show abstract

Preventive Effect of Lactoferrin Intake on Anemia in Female Long Distance Runners

Cited by 24 publications

References 22 publications

A Comparative Study to Evaluate the Efficacy of Oral Lactoferrin Fortified Bovine Colostrum with Oral Iron in the Treatment of Iron Deficiency Anemia

A Comparative Study to Evaluate the Efficacy of Oral Lactoferrin Fortified Bovine Colostrum with Oral Iron in the Treatment of Iron Deficiency Anemia

Radioprotection of mice by lactoferrin against irradiation with sublethal X-rays

Scientific Opinion on bovine lactoferrin

Contact Info

Product

Resources

About